18F-FDG PET/CT作为动脉粥样硬化药物干预研究终点标志物的结构化综述
本结构化综述旨在系统总结以18F-FDG PET作为终点标志物的动脉粥样硬化治疗研究。共纳入18项研究进行数据提取,其中10项探讨降脂治疗后的血管炎症减少,另12项探讨新型抗炎药物对血管炎症的影响。综述认为18F-FDG PET可作为临床干预试验的终点标志物,且他汀类药物在减少血管18F-FDG摄取方面较新型抗炎治疗表现出更一致的效果。
要点
- 18F-FDG PET可无创可视化和量化血管炎症活动。
- 共18项研究纳入数据提取,涵盖降脂和抗炎治疗。
- 他汀类减少血管18F-FDG摄取较新型抗炎药更一致。
核心结论
- 18F-FDG PET可作为临床干预试验中有附加价值的终点标志物。
- 他汀类治疗较新型抗炎治疗在减少血管18F-FDG摄取方面更一致。
研究设计与样本
- 结构化综述,共18项研究符合条件纳入数据提取。
- 其中10项研究探讨降脂治疗后血管炎症减少,12项研究探讨新型抗炎药物对血管炎症的影响。
主要发现
- 持续性血管炎症可能显著贡献于残余心血管风险。
- 他汀类治疗较新型抗炎治疗在减少血管18F-FDG摄取方面更一致。
临床怎么用
- 可将18F-FDG PET作为动脉粥样硬化药物干预试验中评估血管炎症的终点标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammation plays a central role in the initiation, progression, and destabilization of atherosclerotic plaques. Persistent vascular inflammation despite therapeutic intervention may contribute substantially to residual cardiovascular risk. In this context, [18F]fluorodeoxyglucose-positron-emission-tomography ([18F]FDG PET) imaging has emerged as a non-invasive imaging biomarker capable of visualizing and quantifying vascular inflammatory activity in vivo. Previously published studies showed that the use of [18F]FDG PET may provide a non-invasive assessment of arterial inflammation. Accordingly, we aimed to systematically summarize treatment studies using [18F]FDG PET as an endpoint marker. MAIN BODY: 18 studies were considered to be eligible for data extraction. Of these 22 articles, 10 investigated vascular inflammation reduction after trials with lipid-lowering therapies, the other 12 were considering the effect of novel anti-inflammatory drugs on vascular inflammation. CONCLUSION: This review provides an overview of the additional value that [18F]FDG PET can provide as an endpoint marker in clinical intervention trials. Overall, statin therapies demonstrated a more consistent reduction in vascular [18F]FDG uptake compared to novel anti-inflammatory therapies.
引用
- Gijsen CEW, Mottaghy FM, Tawakol A, et al. [18F]FDG PET/CT as an endpoint marker in drug interventional studies in atherosclerosis - a structured review. EJNMMI Res. 2026. PMID: 42690560. doi:10.1186/s13550-026-01489-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。